Business Context and Reporting Period
This Form 6-K filing by Moolec Science SA covers the month of June 2026. The report addresses the Company's regulatory status with the Nasdaq Capital Market following a prior compliance review.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory compliance status rather than financial performance data.
Material Changes
On June 1, 2026, the Nasdaq Hearings Panel notified Moolec Science SA that it has regained compliance with all previously cited continued listing requirements. Specifically, the Company is now compliant with:
- Nasdaq Listing Rule 5250(c)(1) regarding periodic financial reporting.
- Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price requirement.
- Nasdaq Listing Rule 5550(b)(1) regarding the minimum stockholders' equity requirement.
Outlook, Risks, and Management Commentary
Despite regaining compliance, the Panel has imposed a discretionary monitoring period of one year pursuant to Nasdaq Listing Rule 5815(d)(4)(A). Additionally, the Company is subject to a mandatory panel monitor for one year regarding financial reporting and stockholders' equity requirements under Rule 5815(d)(4)(B). Management intends to continue monitoring compliance but explicitly states there can be no assurance that the Company will maintain compliance with all applicable Nasdaq requirements in the future.
Investor Verification Checklist
- Verify the Company's current stock price to ensure it remains above the minimum bid price requirement.
- Confirm the Company's stockholders' equity levels remain above the minimum threshold.
- Monitor the timely filing of future periodic financial reports to avoid relisting issues.
- Review the specific terms of the mandatory panel monitor to understand reporting obligations during the one-year monitoring period.